Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 1—January 2010
Research

Methicillin-Resistant and -Susceptible Staphylococcus aureus Infections in Dogs

Meredith C. FairesComments to Author , Michelle Traverse, Kathy C. Tater, David L. Pearl, and J. Scott Weese
Author affiliations: University of Guelph, Guelph, Ontario, Canada (M.C. Faires, D.L. Pearl, J.S. Weese); University of Pennsylvania, Philadelphia, Pennsylvania, USA (M. Traverse); Angell Animal Medical Center, Boston, Massachusetts, USA (K.C. Tater)

Main Article

Table 2

Univariable analysis of medical and surgical risk factors for MRSA versus MSSA infections in dogs, United States and Canada, 2001–2007*

Variable† MRSA, no. (%) dogs, n = 40 MSSA, no. (%) dogs, n = 80 Odds ratio (95% CI) p value‡
Received antimicrobial drugs
No 8 (20.0) 30 (37.5) Ref
Yes 26 (65.0) 33 (41.3) 3.84 (1.21–14.74) 0.02
Don’t know
6 (15.0)
17 (21.2)
1.29 (0.28–5.65)
0.75
Received >2 antimicrobial drugs
No 25 (62.5) 56 (70.0) Ref
Yes 9 (22.5) 7 (8.8) 2.87 (0.81–11.49) 0.08
Don’t know
6 (15.0)
17 (21.2)
0.79 (0.19–2.79)
0.78
Received an aminoglycoside
No 8 (20.0) 30 (37.5) Ref
Yes 1 (2.5) 1 (1.3) 5.71 (0.06–517.45) 0.30
Other classes§ 25 (62.5) 32 (40.0) 3.80 (1.19–14.62) 0.02
Don’t know
6 (15.0)
17 (21.2)
1.29 (0.28–5.62)
0.75
Received a β-lactam
No 8 (20.0) 30 (37.5) Ref
Yes 18 (45.0) 25 (31.3) 3.58 (1.04–14.79) 0.04
Other classes 8 (20.0) 8 (10.0) 4.18 (0.96–20.88) 0.04
Don’t know
6 (15.0)
17 (21.2)
1.31 (0.28–5.69)
0.75
Received chloramphenicol
No 8 (20.0) 30 (37.5) Ref
Yes 1 (2.5) 2 (2.5) 2.61 (0.04–65.5) 1.00
Other classes 25 (62.5) 31 (38.8) 3.84 (1.21–14.74) 0.02
Don’t know
6 (15)
17 (21.2)
1.29 (0.28–5.65)
0.75
Received a fluoroquinolone
No 8 (20.0) 30 (37.5) Ref
Yes 9 (22.5) 7 (8.8) 5.34 (1.24–27.38) 0.01
Other classes 17 (42.5) 26 (32.5) 3.24 (0.94–13.2) 0.06
Don’t know
6 (15.0)
17 (21.2)
1.31 (0.29–5.74)
0.75
Received a lincosamide
No 8 (20.0) 30 (37.5) Ref
Yes 2 (5.0) 2 (2.5) 4.43 (0.27–75.86) 0.19
Other classes 24 (60.0) 31 (38.8) 3.77 (1.18–14.53) 0.02
Don’t know
6 (15.0)
17 (21.2)
1.32 (0.29–5.73)
0.75
Received a nitroimidazole
No 8 (20.0) 30 (37.5) Ref
Yes 2 (5.0) 0 7.18 (0.53–∞) 0.07
Other classes 24 (60.0) 33 (41.3) 3.47 (1.08–13.33) 0.03
Don’t know
6 (15.0)
17 (21.2)
1.38 (0.29–6.17)
0.74
Received a tetracycline
No 8 (20.0) 30 (37.5) Ref
Yes 2 (5.0) 1 (1.3) 6.63 (0.29–463.75) 0.17
Other classes 24 (60.0) 32 (40.0) 3.54 (1.11–13.65) 0.03
Don’t know
6 (15.0)
17 (21.2)
1.33 (0.29–5.88)
0.74
Hospitalized
No 16 (40.0) 38 (47.5) Ref
Yes 16 (40.0) 25 (31.3) 1.54 (0.58–4.14) 0.37
Don’t know
8 (20.0)
17 (21.3)
1.17 (0.32–4.06)
0.08
Underwent surgical procedure
No 25 (62.5) 46 (57.5) Ref
Yes 10 (25.0) 16 (20.0) 1.07 (0.39–2.83) 1.00
Don’t know 5 (12.5) 18 (22.5) 0.45 (0.09–1.68) 0.26

*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; CI, confidence interval; Ref, referent category. Dogs with MRSA (case-patients) and MSSA (controls) infections were matched for veterinary referral hospital and date of admission.
†Information obtained refers to the 90 days before admission to the veterinary referral hospital.
‡Score method for estimating p values does not assume a symmetrical distribution for discrete data. p<0.05 was considered significant.
§Refers to dogs given antimicrobial drugs from other drug classes.

Main Article

Page created: March 31, 2011
Page updated: March 31, 2011
Page reviewed: March 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external